Rybelsus Tablet
Product Images NDC 0169-4307

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rybelsus (NDC 0169-4307). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk Pharmaceutical Industries, Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image 01)

FDA Label Image

Figure 1 (Image 02)

Not available.*

FDA Label Image

3mg Bottle (Image 03)

RVBELSUS® 3mg is a medication in tablet form containing 3mg of semaglutide. It is intended for oral use only and should be dispensed with a medication guide. Any unreadable text is excluded from this description.*

FDA Label Image

Figure 4 (Image 05)

FDA Label Image

3mg Trade (Image 08)

FDA Label Image

7mg Trade (Image 09)

RYBELSUS® is a once-daily tablet medication containing semaglutide at a strength of 7mg. It is intended for oral use and is available for prescription only. It is recommended to provide patients with an enclosed medication guide.*

FDA Label Image

14mg Trade (Image 10)

FDA Label Image

7 Bottle (Image 12)

RVBELSUS® 7mg is a medication in tablet form containing semaglutide. It is intended for oral use only and should be taken once a day. Unfortunately, additional information about this medication is not available due to the limited text provided.*

FDA Label Image

14 Bottle (Image 13)

RYBELSUS® 14 mg (semaglutide) Tablets are a medication intended for daily use. Unfortunately, the rest of the text is not readable.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.